Form 4: BioLife Solutions Executive Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions, sold 240 shares of common stock at $27.02 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Sarah Aebersold, the Chief Human Resources Officer of BioLife Solutions, sold 240 shares of the company's common stock on January 6, 2025.
- The shares were sold at a price of $27.02 per share.
- This transaction was executed under a pre-existing Rule 10b5-1 trading plan adopted by Ms. Aebersold on January 3, 2023.
- The sale was made to cover tax withholding obligations related to the vesting of restricted stock.
- Following the transaction, Ms. Aebersold directly owns 60,244 shares of BioLife Solutions common stock.
Sentiment
Score: 5
Explanation: The document describes a routine stock sale by an executive under a pre-arranged plan. It is a neutral event with no significant positive or negative implications for the company's performance or outlook.
Industry Context
This is a routine transaction for executives who use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading. It is common for executives to sell shares to cover tax obligations related to vesting stock.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and life sciences sectors, such as Thermo Fisher Scientific and Danaher.
- These plans allow executives to sell shares at predetermined times and prices, avoiding potential accusations of insider trading.
- The sale of 240 shares by Ms. Aebersold is a relatively small transaction compared to the overall trading volume of BioLife Solutions and is not unusual for executives managing their personal finances and tax obligations.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's stock price given the small volume and pre-planned nature of the transaction.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Date the 10b5-1 trading plan was adopted by Sarah Aebersold. |
| 01/06/2025 | Date of the stock sale transaction. |
| 01/08/2025 | Date the Form 4 was signed. |
Keywords
BioLife Solutions, BLFS, insider trading, Form 4, 10b5-1 plan, stock sale, executive, Sarah Aebersold, share transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.